- Molecular NameGlipizide
- SynonymGlipizida [INN-Spanish]; Glipizidum [INN-Latin]; Glydiazinamide
- Weight445.544
- Drugbank_IDDB01067
- ACS_NO29094-61-9
- Show 3D model
- LogP (experiment)1.9
- LogP (predicted, AB/LogP v2.0)2.43
- pka5.9
- LogD (pH=7, predicted)0.63
- Solubility (experiment)0.0372 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.61
- LogSw (predicted, AB/LogsW2.0)0.09
- Sw (mg/ml) (predicted, ACD/Labs)0.27
- No.of HBond Donors3
- No.of HBond Acceptors9
- No.of Rotatable Bonds7
- TPSA138.53
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn oral medium-to-long acting anti-diabetic drug from the sulfonylurea class.
- Absorption_value100.0
- Absorption (description)Readily absorbed after oral administration.
- Caco_2N/A
- Bioavailability95.0
- Protein binding98.4
- Volume of distribution (VD)0.17 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolised by hydroxylation to form a number of inactive metabolites, principally the 4-trans-hydroxycyclohexyl and 3-cis-hydroxycyclohexyl derivatives.
- Half life3.4 h
- ExcretionAbout 65 to 85% of a dose is excreted in the urine in 24 h, with about 3 to 10% as unchanged drug, up to 80% as hydroxylated metabolites, mainly the 4-trans-hydroxycyclohexyl derivative, and about 1 to 2% as an N-acetamido metabolite; about 11% of a dose is eliminated in the faeces.
- Urinary Excretion<5
- Clerance0.52 ml/min/kg
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A